Jung Yeoun Su, Kim Kyeong Ok, Lee Si Hyung, Jang Byung Ik, Kim Tae Nyeun
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Korean J Gastroenterol. 2016 Feb;67(2):74-80. doi: 10.4166/kjg.2016.67.2.74.
BACKGROUND/AIMS: Although intravenous proton pump inhibitor (PPI) has been used for the prevention of post endoscopic submucosal dissection (ESD) bleeding, the route of administration has not been confirmed. The aim of the present study was to compare the efficacy of intravenous and oral PPI administration for the prevention of delayed post ESD bleeding.
Total 166 consecutive patients were randomly assigned to 30 mg lansoprazol twice a day (PO group) and 120 mg pantoprazole intravenous injection (IV group) for 48 hours. Finally, 65 patients in PO group and 87 patients in IV group were analyzed. After ESD, all patients underwent follow up endoscopy after 24 hours and were observed the symptoms of bleeding up to 60 days after ESD.
Age, sex and use of anticoagulants were not different between groups. At follow up endoscopy after 24 hours, oozing and exposed vessel was noted in 4.6% of PO group and 8.0% of IV group and there was no significant difference. Delayed bleeding occurred in 4 of 65 patients (6.2%) in the PO group and 8 of 87 patients (9.2%) in the IV group (p>0.999). By multivariate analysis, oozing or exposed vessels at follow up endoscopy were risk factors for delayed bleeding (OR=17.5, p=0.022).
There was no significant difference in the delayed bleeding, length of hospital stay according to the administration route. Bleeding stigmata at follow up endoscopy was risk factor of delayed bleeding. Oral PPI administration can cost-effectively replace IV PPI for prevention of post ESD bleeding.
背景/目的:尽管静脉注射质子泵抑制剂(PPI)已用于预防内镜黏膜下剥离术(ESD)后出血,但给药途径尚未得到证实。本研究的目的是比较静脉注射和口服PPI预防ESD后延迟出血的疗效。
将166例连续患者随机分为两组,一组每天两次口服30 mg兰索拉唑(口服组),另一组静脉注射120 mg泮托拉唑(静脉注射组),持续48小时。最后,对口服组的65例患者和静脉注射组的87例患者进行分析。ESD术后,所有患者在24小时后接受随访内镜检查,并观察ESD后60天内的出血症状。
两组患者的年龄、性别和抗凝剂使用情况无差异。在24小时后的随访内镜检查中,口服组4.6%的患者和静脉注射组8.0%的患者出现渗血和血管暴露,差异无统计学意义。口服组65例患者中有4例(6.2%)发生延迟出血,静脉注射组87例患者中有8例(9.2%)发生延迟出血(p>0.999)。多因素分析显示,随访内镜检查时的渗血或血管暴露是延迟出血的危险因素(OR=17.5,p=0.022)。
根据给药途径,延迟出血、住院时间无显著差异。随访内镜检查时的出血迹象是延迟出血的危险因素。口服PPI可经济有效地替代静脉注射PPI预防ESD后出血。